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Diffuse high grade gliomas are complex and lethal neoplasms of the
adult central nervous system that are driven by a range of genetic and epige-
netic alterations. Molecular classification of these tumors has identified dif-
ferent transcriptional subtypes, the most notable being Proneural (PN) and
Mesenchymal (MES) classes. The most aggressive forms of the disease have
a Mesenchymal expression signature, with reported PN-to-MES transition oc-
curring with tumor progression. Master regulatory analysis has identified the
transcriptional co-activator TAZ (WWTR1) as a major driver of the MES transi-
tion. Overexpression of this single protein in glioma stem cells has been shown
to drive a transition from a PN to MES cell state. In this study, we explore in
depth the consequences of high TAZ expression in clinical glioma samples. We
show that TAZ-high gliomas associate with immune infiltration and extracellu-
lar matrix genes, whereas TAZ-low gliomas associate with neuronal develop-
ment genes. Furthermore, TAZ overexpression causes widespread epigenetic
alterations in the cell, with consequent silencing of neuronal differentiation
factors and an activation of mesenchymal regulators. Directed differentiation
of glioma stem cells towards the post-mitotic neuronal state have been shown
to be efficient strategies to battle this disease. By establishing the role of TAZ
in suppressing the neuronal state in these cells, we argue that silencing of
TAZ and/or its effector molecular complexes through therapeutics is a viable
strategy. Given that TAZ has been found to be largely dispensable for normal
tissue homeostasis, directed targeting of this protein is an attractive potential
avenue in finding a cure for GBM.
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1
I N T R O D U C T I O N
1.1. adult gliomas
Diffuse infiltrative gliomas are the most common forms of adult primary brain
tumors, with an estimated incidence rate of 6.6 per 100,000 individuals in the
USA [1]. Molecular genetic evidence has been presented to show that these
tumors originate from neural stem and progenitor cells in the subventricular
zone of the brain [2]. They are characterized by diffuse growth and exten-
sive infiltration of the tumor cells into the surrounding stromal regions and
are associated with poor clinical outcome [3]. Traditionally, they have been
classified and graded into subtypes based on appearance of the tumor cells
and surrounding tissues under the microscope. Due to the morphological
similarity of the tumor cells to the supporting glial cells in the brain, these
tumors are classified as Astrocytomas, Oligodendrogliomas and Oligoastro-
cytomas [4]. Based on histopathological criteria such as nuclear atypia, cell
density, presence of tumor microvasculature and tissue necrosis, gliomas are
classified into WHO grades I-IV. Grade I gliomas are mostly benign tumors
having none of the aforementioned features, frequently curable with surgical
resection with low recurrence rates, while grade II gliomas have cytological
12
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atypia alone [4]. Grade I/II tumors are considered low grade gliomas (LGGs)
and together constitute about 17-22% of adult primary brain tumors [1]. LGGs
frequently occur in young adults and are characterized by a low mitotic index.
Median survival rate is five to thirteen years, depending on molecular subtype
of the tumor that will be discussed in the sections below [5]. Treatment op-
tions include extensive surgical resection of the tumor, followed by radiation
therapy and chemotherapy with the alkylating agent Temozolomide. However,
given the highly diffuse nature of these tumors, complete surgical resection is
not possible, and nearly all cases of grade II tumors recur and show malignant
progression to high grade gliomas [7, 6].
Malignant high-grade gliomas, especially glioblastomas, constitute the
largest fraction of adult brain tumors. They include grade III anaplastic gliomas
(astrocytomas and oligodendrogiomas) and grade IV glioblastoma multiforme
(GBM). These diseases are associated with high morbidity and mortality, with
median survival of 12-15 months for GBM and 2-5 years for anaplastic gliomas
[8]. They are essentially incurable. About 80% of GBM cases occur de novo
in older patients with a median age of 64 years and are classified as primary
GBM [9]. Secondary GBM cases are seen in younger patients (median age
45 years), and are cases of progression from pre-existing lower grade gliomas
[10]. It is not possible to distinguish between the primary and secondary GBM
cases based on imaging and histopathology, although molecularly they have
very different origins, and also have significantly different treatment responses
[11].
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1.2. molecular classification of gliomas
Although histological classification has remained the gold standard for glioma
diagnostics and grading, it suffers from considerable intra- and inter-observer
variability [12]. Furthermore, numerous studies have established that cluster-
ing glioma cases based on their molecular features such as genetic mutations,
gene expression and DNA methylation profiles shows better correlation with
clinical outcomes, than histological classification [13, 14, 15, 16]. Our growing
understanding of the molecular genetics of this disease was leveraged in the
revised 2016 WHO Classification of Tumors of the CNS [17], which employs
histological features as well as newly established molecular genetic markers of
the disease for integrated disease diagnosis [17].
Large scale multi-omics analyses of hundreds of patient tumor samples
of grade II-IV gliomas by The Cancer Genome Atlas and other independent
groups [18, 19, 20, 22] over the past decade have provided a wealth of infor-
mation regarding the altered genetic and epigenetic landscapes of this dis-
ease. A key breakthrough from these studies has been the identification of
recurrent mutations in the Isocitrate De-hydrogenase (IDH) gene as a distinct
and frequently observed characteristic of low grade gliomas and secondary
glioblastomas [18, 23]. The IDH 1 and IDH2 genes encode cytoplasmic and
mitochondrial metabolic enzymes that are part of the respiratory pathway re-
spectively. The wild type enzymes, as part of the citric acid cycle, catalyze
the conversion of isocitrate to alpha ketoglutarate (αKG). The observed IDH
mutations in gliomas were predominantly heterozygous and missense events
[24]. The mutant enzymes lose their ability to bind Isocitrate and therefore its
normal catalytic activity [25]. Biochemical and structural studies established
that the mutations were part of the active site of the enzyme, and were neo-
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morphic gain of function events [26, 27]. The mutant enzymes were found
to metabolize αKG, the product of wild type IDH activity, into the molecule
2-hydroxyglutarate (2HG) [26, 27].
Furthermore, 2HG was shown to inhibit the activity of several αKG de-
pendent dioxygenase enzymes, including several histone and DNA demethy-
lating enzymes that are involved in epigenetic control of the cell[28]. Large
scale genome wide DNA methylation analysis of tumor samples revealed that
nearly all IDH mutant gliomas were associated with a distinct DNA methyla-
tion profile, exhibiting a global CpG island hypermethylation phenotype (G-
CIMP) [29]. This severe alteration of the epigenetic landscape in these tumors
turns out to be exceedingly consequential, resulting in promoter hypermethy-
lation and silencing of a large number of genes [29]. Gliomas with the IDH
mutations demonstrate very different biology and clinical course than the IDH
WT tumors [30], being associated with significantly better patient prognosis
and treatment responsiveness. The IDH mutation status therefore happens
to be the principal determinant in accurate molecular subtyping of gliomas
[20, 17].
Clustering of IDH mutant tumors has identified three distinct epigenetic
groups: cases with loss of heterozygosity at chromosome arms 1p and 19q
(1p/19q codel) which are low grade oligodendrogliomas, and non-codel cases
with or without the G-CIMP phenotype [21]. The codel cases also harbor fre-
quent mutations in CIC, FUBP1, PIK3CA, NOTCH1 and TERT genes, while
the non-codel cases are associated with TP53 mutations and loss of function
alterations in ATRX. The non-codel cases also show frequent focal amplifica-
tions in loci carrying the PDGFRA, CDK4 and MYC genes [21]. Interestingly,
the IDH mutant gliomas without the G-CIMP phenotype have very poor prog-
nosis compared to the other two IDH mutant subgroups [20], indicating that
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the survival benefits of having the IDH mutation are at least in part a con-
sequence of an altered gene expression signature caused by the CpG island
hypermethylation and transcriptional silencing [20].
1.3. transcriptomic subtypes of gliomas
Based on tumor-cell intrinsic transcriptional signatures, the IDH WT gliomas
most consistently cluster into three different subgroups, namely the Proneural
(PN), Classical (CL) and MESenchymal (MES) subtypes [32]. The PN sub-
type of tumors are associated with higher expression of neural developmental
genes, while the MES subtype is enriched for genes involving extracellular ma-
trix (ECM) and immune regulation. The original study by Phillips et al. [34],
followed by others [33, 35] have shown significant survival differences between
these two subtypes. In terms of molecular alterations, the PN subtype is asso-
ciated with high frequency of TP53 mutations and amplification of PDGFRA
and CDK4 genes [32, 36, 19]. The CL subtype is associated with chr7 ampli-
fication and chr10 deletions, EGFR amplification and homozygous deletion of
Ink4a/ARF locus [32, 36, 19]. The MES subtype is strongly associated with
NF1 inactivation, a known driver event for this subtype [32, 37, 38].
Gliomas of the PN subtype on initial diagnosis generally recur in a MES
state, suggesting a PN to-MES transition can occur in patient tumors, although
this notion remains controversial. Recent genome wide analyses of matched
primary and recurrent GBMs however highlight the plasticity among the tran-
scriptiome subtypes and notably a switch to the MES subtype upon recurrence
was associated with worse outcome [32]. To the contrary, single-cell sequenc-
ing studies reveal improved survival rates in patients with tumors that had
a higher proportion of cells with a pure PN signature [39]. Blockade of MES
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trans-differentiation and inducing PN features may be an attractive strategy for
GBM treatment. Notably, grade II IDH-MUT gliomas exhibit predominantly
PN features associated with significantly higher survival rates [20].
Given the finding that the MES subtype of gliomas are consistently asso-
ciated with worse prognosis, and numerous studies having showed that this
signature is indeed glioma cell intrinsic and not just an artefact of the tumor
microenvironment [40], studies have been undertaken to study the origins of
a mesenchymal cellular state in glioma cells that largely derive from the neu-
roectoderm [41, 42]. These studies employed an information theoretic algo-
rithm called ARACNE to infer causal regualtory interactions between genes
in the gene expression data, thereby inferring the regulome, i.e. the list of
genes whose expression is significantly controlled by each transcription fac-
tor (TF) [43]. By using the gene expression data in TCGA for GBM sam-
ples, they built a GBM-specific regulome for each TF. Then, by performing
an over-representation analysis, they identified TFs whose regulomes were sig-
nificantly enriched for the MESenchymal signature genes, thereby identifying
master regulators of the MES cell state [41]. Using this approach, the origi-
nal study identified six transcription factors, namely Stat3, C/EBP, bHLH-B2,
Runx1, FosL2, and ZNF238 as controlling over 74% of the mesenchymal target
genes [41].These TFs were also found to form auto-regulatory loops amongst
themselves, with each gene driving the expression of the other. STAT3 and
CEBP-B were found to be at the apex of this circuit, driving the expression of
the other master regulators as well as the downstream target genes. These two
genes were further shown to be both necessary and sufficient for establishing
the MES signature [41].
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1.4. taz as a master regulator of mes gliomas
In a follow-up study employing the same algorithm, but by including more
GBM cases from TCGA as well as a larger set of potential master regulators
by including transcriptional co-activators in the analysis, Bhat et al. estab-
lished that overexpression of the transcriptional co-activator TAZ is sufficient
for reprogramming PN glioma stem cells (GSCs) to a MES state [42]. Having
first identified TAZ as a master regulator using network analysis, the authors
went on to establish a number of results about the effects of TAZ expression in
gliomas. Given the relevance of these results to this work, they are presented
in greater detail below:
• The TAZ inferred MES network targets were relatively non-overlapping
with those of STAT3 and CEBP-B.
• TAZ expression in the TCGA samples strongly correlated with a MES
metagene score generated from the union of Phillips[34] and Verhaak[36]
signatures.
• TAZ promoter is significantly hypermethylated in the PN gliomas, with
consequent downregulation of gene expression.
• TAZ expression is lower in long-term (> 1 year) versus short-term sur-
vivors (< 1 year).
• Nuclear localization of TAZ, as determined using IHC staining, was
found to be predictive of poor patient survival.
• TAZ expression, and not YAP, is reflective of the MES nature of cultured
patient-derived glioma stem cells. The PN GSCs were hypermethylated
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at the promoters of TAZ. Treatment with the demethylating agent 5-aza-
2’-deoxycytidine (DAC) induced TAZ expression and consequent MES
transformation of these cell lines revealing an epigenetic mechanism of
regulation of TAZ expression in gliomas. TAZ expression is essential for
expression of mesenchymal markers, invasive, self-renewal and tumor
initiation capacities of GSCs.
• Interaction with TEAD family of transcription factors, in particular TEAD2
and TEAD4, is essential for TAZ functional activity.
• TAZ can reprogram primary neural stem cells (NSCs) to express mes-
enchymal markers, showing that TAZ-induced effects on GSCs is not
contingent on pre-existing background genetic alterations.
• TAZ is a direct inducer of MES transformation, independent of the pre-
viously established master regulators STAT3 and CEBP-B.
• TAZ overexpression drives upregulation of MES signature genes, and
downregulation of PN genes, establishing TAZ as a master modulator of
a PN to MES transition in gliomas.
• TAZ is directly recruited to the promoters of a majority of MES signature
genes, and recruitment of TAZ is essential for induction of these genes.
• The RCAS-TV-A system is a widely used gene delivery system for mod-
eling human cancers in mice [44]. It is based on the specific interaction of
the RCAS family of retroviral vectors with the Tumor Virus A (TVA) re-
ceptor expressed on the surface of target cells. By generating transgenic
mice models expressing the TVA receptor on the surface of specific cell
types, targeted gene delivery to tissues of interest can be achieved. In
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vivo experiments using the RCAS/N-tv-a mouse model system in this
study showed that concomitant overexpression of TAZ and PDGF-B di-
rectly in the neural progenitor cells of murine brains drives mesenchymal
transformation of otherwise PN low grade gliomas and their progression
to higher grades.
In summary, master regulatory analyses have established that the tran-
scription factors STAT3, CEBPB and TAZ independently [42] effect a cell state
transition from a proneural to a mesenchymal nature in gliomas, giving rise
to an aggressive form of the disease with significantly worse patient morbidity
and mortality.
1.5. how cell identities are defined
The PN to MES transition is essentially a change in the cell state from one
characterized by high levels of expression of genes involved in neuronal differ-
entiation and function (as is expected in neural stem cells, from which these
cancers are believed to originate [2]) to an aberrant genetic profile that is char-
acteristic of mesenchymal cells (trans-differentiation). Distinct cell states are
established by the activity of different lineage-specific transcription factor net-
works [45, 46]. To use the popular metaphor of Waddington’s landscape [47],
developmental specification is akin to cells rolling down a hill with branching
canals, each determining a distinct differentiated state. The branches are estab-
lished by differential activation of different transcription factor genes, with spe-
cific networks of transcription factor activity characterizing each branch [48].
In addition to having the activation of lineage specific transcription factors,
the differentiated states are made robust to aberrant transcriptional activity
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and stochastic cellular reprogramming by increasing the heights of the walls
between different canals through epigenetic alterations of the DNA [46, 49, 50].
The DNA is wrapped around histone octamers to form nucleosomes and
other higher order chromatin structures that ensure efficient packaging within
cells [51]. Chemical modifications of these histone proteins affect the strength
of their interactions with the DNA backbone, and allow for differential acces-
sibility of different regions of the genome across cell types [52, 53, 50]. By
sequestering parts of the genome that are not required for the given cell state
in regions of closed chromatin, which are highly condensed and are not ac-
cessible for binding by the regulatory machinery, the different cell states are
reinforced as being distinct entities [46, 49, 54].
In addition to the promoters which lie proximal to the genes’ transcrip-
tion start sites, gene expression is strongly regulated by distal regulatory re-
gions called enhancers [55, 56]. These are regions of the genome that are a
few hundred base pairs long and interact with their target promoters through
chromatin looping [57]. Numerous transcription factors bind at the enhancer
and recruit components of the transcription machinery to the target promoters
to vastly increase gene activity[58]. Differential enhancer activity determined
by chemical modifications like methylation and acetylaiton of the histone tails,
such as H3K4me1 and H3K27ac marks, are well established mechanisms by
which distinct cell states are established[56, 59].
1.6. epigenetic regulation by TAZ
From the above discussions, it is clear that in order to effect the PN to MES tran-
sition, the identified master regulators must be capable of driving epigenetic
changes in the cell that would lower the walls between the different cell states
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and be able to activate a core regulatory circuit characteristic of the alternative
cell fate [48, 60].
TAZ and its paralog YAP are the core effectors of the evolutionarily con-
served Hippo signaling pathway[61]. The Hippo pathway involves a cascade
of kinases that are activated in response to a diverse range of upstream stimuli,
and allows the cell to sense and integrate information about the biophysical
and chemical properties of its microenvironment [61]. Signaling through this
pathway regulates the subcellular localization and concentration of YAP/TAZ
[62, 63]. In the absence of hippo signaling, YAP/TAZ are present in the nu-
cleus, where they function as transcriptional coactivators. Nearly all the es-
tablished functions of YAP/TAZ depend on their interaction with the TEAD
family of transcription factors [64]. The YAP/TAZ-TEAD complex is known
to predominantly bind to the distal enhancer sites of target genes, and affect
transcriptional activity by recruiting components of chromatin remodeling and
transcriptional machinery [65, 66, 67].
In the context of our earlier discussions regarding how master regulators
facilitate a switch in cell fates, YAP/TAZ have been shown to directly interact
with a range of epigenetic remodeling complexes that control transcriptional
states such as the SWI/SNF complex, GAGA factor, Mediator complex, Ncoa6,
and the NuRD complexes [68]. YAP/TAZ activity has been found to be crit-
ical for a range of human cancers, driving cancer initiation, progression and
metastases [64]. Their activity has been proposed to underlie the formation
and maintenance of cancer stem cell fractions within the tumors [69], as well as
facilitate the transcriptional addiction that is characteristic of cancer [70]. Tran-
scriptional addiction is the phenomenon where the dysregulated transcription
control programs in cancer lead to the cells becoming highly dependent on
certain molecular regulators of gene expression [71]. Although largely charac-
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terized as being a transcriptional co-activator, recent work has shown that TAZ
interacts directly with the Nucleosome remodeling and deacetylase(NuRD)
complex and thereby suppress the expression of certain target genes [72]. The
NuRD complex is an ATPase dependent chromatin remodeler with histone
deacetylase activity. By recruiting this complex to certain target sites, TAZ is
able to shut down the expression of these genes through compaction of their
regulatory regions [73]. This is so because upon deacetylating the histone tails,
the negatively charged DNA backbone now wraps tightly around the posi-
tively charged histone proteins, thereby inhibiting the binding of transcription
factors and other regulatory complexes essential for gene expression. Presence
of active histone marks at the cis-regulatory regions is therefore essential to
have high levels of gene expression.
1.7. summary
In conclusion, gliomas are a complex disease of the adult central nervous sys-
tem, driven by a range of genetic and epigenetic alterations. One of the char-
acteristic molecular characteristics of gliomas is the presence or absence of the
IDH mutation, which has, since its discovery only about a decade ago, been
identified to be the most influential molecular markers for clinical course of
the disease and patient survival. Based on gene expression signatures, two
important clusters have been defined, namely the PN and MES subtypes. The
IDH-MUT cases tend to be predominantly PN. A shift from the PN to MES
subtype has been seen to occur in some cases of disease progression. Key reg-
ulators of the MES expression subtype have been identified, and include the
TFs STAT3, CEBP-B and TAZ.
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In addition to its role in driving tumor growth and aggressiveness in
gliomas, the YAP/TAZ-TEAD complex has since been found to be a key reg-
ulator of cell proliferation, survival, metabolism, differentiation and cell fate,
and to underlie many of the key hallmark properties of cancer [61, 64, 74].
This thesis explores the consequences of high TAZ expression in clinical
glioma samples as well as cultured patient-derived glioma stem cells. The un-
derlying hypothesis that is tested here is that high levels of TAZ expression in
the transformed neural progenitor cells (glioma stem cells) actively suppresses
their progression down the neuronal lineage through disruption of the cell’s
epigenetic landscapes, leading to the establishment of an aberrant chromatin
and transcriptional state. This is achieved through integrated analysis of se-
quencing data that reveals the chromatin and gene expression signatures of
the cells.
2
M E T H O D S
2.1. tcga data acquisition and pre-processing
Raw gene expression counts data for RNA-sequenced primary tumor samples
of LGG and GBM cohorts were downloaded from Genomic Data Commons
(GDC) and processed using the TCGAbiolinks [81] R package. Within and be-
tween lane normalization of the raw read counts were carried out using the
EDAseq package [75]. Genes in the lowest quartile by total expression were fil-
tered out, yielding a data frame with 661 cases and 14,477 genes. Clinical data
for these samples were also downloaded from GDC. For survival information,
I used the standardized patient survival dataset provided with Liu et al 2018
[76], and used the duration of Progression Free Interval (PFI) for all analyses
[76]. Tumor purity estimates were derived from data published in Aran et al
2015 [80], which gave the ESTIMATE [77] stromal, immune and overall purity
score for each sample in TCGA. All other clinical data presented here are from
GDC.
25
2.2 rna sequencing data analysis 26
2.2. rna sequencing data analysis
For differential gene expression analysis of the TCGA data, the raw gene ex-
pression counts was imported using the tximport [82] package and analyzed
using DESeq2 [83]. Variance stabilizing normalization of the counts data
was performed using the vst function for the purpose of visualization like
generating principal component analysis (PCA) plots and heatmaps. In all
cases, correction for multiple hypothesis testing was done using the Benjamini-
Hochberg method [87]. Genes passing fold change cutoffs of either 1.5× or 2×
at an FDR threshold of 0.05 were considered significant in different analyses, as
indicated in the text. In all cases, the fold change considered was the posterior
estimated mean after effect size shrinkage [84]. Heatmaps of the differentially
expressed genes were created using the ComplexHeatmap package [85] in R.
Enrichment analysis and visualization for either Gene Ontology or path-
ways were done using the ClusterProfiler [88] package in R, or using PAN-
THER from the Gene Ontology Consortium website (http://geneontology.org/docs/go-
enrichment-analysis/). Master regulator analysis of lists of significant genes
were done using ChEA3 (https://amp.pharm.mssm.edu/chea3/) [89]. This is
an online tool that identifies Master regulators by testing overlap between lists
of query genes and previously annotated TF targets, assembled from multiple
sources. The top ’n’(=100) Master regulators prioritized by average integrated
rank across multiple libraries were further studied.
For the RNA-seq data generated from cultured glioma stem cells (GSCs),
I used the following pipeline. I used Kallisto [90] for (pseudo-)aligning reads to
the hg19 ensembl human transcriptome build. The number of pseudo-aligned
reads varied from 15 to 40 million across the nine samples analyzed. Transcript
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counts were imported and summarized to gene level using tximport [82], and
between sample normalization was carried out in DESeq2. For studying the
effects of TAZ overexpression on the gene expression profile of glioma stem
cells (GSCs), expression profiles of the 4SA samples were contrasted with vec-
tor and S51A samples. Significance thresholds used were FDR < 0.05 and
log-2 fold change (LFC) > 1.
2.3. chromatin immunoprecipitation sequencing data analysis
Chromatin Immunoprecipitation followed by sequencing (ChIP-seq) data was
generated for histone modification marks for active chromatin H3K4me1, H3K4me3
and H3K27Ac in patient derived glioma stem cell lines with or without TAZ
overexpression. The antibodies used for the experiments were: H3K4me1 (Ab-
cam ab8895), H3K27ac (Abcam ab4729) and H3K4me3 (Abcam ab8580). The
reads were trimmed to remove adapter sequences and low quality bases using
trim-galore [91], using a quality filter of 20, stringency of 2 and min-length
threshold of 25bps. Trimmed reads were then aligned to the hg19 human
genome build using bowtie [92], allowing for up to two mismatches, retaining
only the best mapping positions and removing reads mapping to over three
positions in the genome. ChIP-peaks were called using MACS2 [93] with a p-
value threshold of 1e-6. Differential peaks between conditions were also called
using MACS. Super enhancers were called using ROSE [94] on H3K27ac peaks
that were differential between vector and 4SA transfected GSC11 cells using
default settings.
Distal Enhancer peaks were mapped to differentially expressed target
genes using the enhancer-promoter maps presented in Cao et al [95]. Tests for
specific association of super enhancer domains with target genes was carried
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out using the fisher.test function in R. Heatmaps of ChIP-seq signal intensity at
genomic regions of interest were plotted using deeptools [97], using the RPKM-
normalized, input subtracted bigwigs. BigWig files were visualized using IGV
[98] to demonstrate peak enrichment at select promoter sites.
2.4. survival analyses
Univariate and multivariate Cox regression analyses were carried out using
the survival package in R [78]. For the multivariate Cox regression, I stratified
samples by their IDH status to test significance of TAZ expression in the IDH-
WT and IDH-MUT groups separately. Survival plots were created using the
survminer package [79] in R. Significance of differential survival of TAZ-low
and TAZ-high cases was tested using log-rank test after stratifying patients by
IDH Status.
2.5. data generation protocols∗
∗The following protocols were used in Prof. Bhat’s lab by Dr. Alessandra
Audia to generate samples for sequencing.
2.5.1. rna sequencing data generation
Total RNA from GSCs samples was isolated with Quick-RNA MiniPrep Kit,
Zymo Research according to the manufacturer’s instructions and DNA was
eliminated (Dnase I, Zymo Research). The total RNA was eluted in a volume
larger than 15µl and quantified using the NanoDrop spectrophotometer. At
least 20ng/µl of total RNA extracted from GSCs samples were shipped to the
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Genome sequencing company Novogene for quality control and RNA sequenc-
ing.
2.5.2. chromatin immunoprecipitation sequencing data generation
To prepare the samples for Chip-seq, GSCs were crosslinked adding 1% final
formaldehyde concentration and incubated exactly for 10’ while shaking. 2.5M
Glycine was then added to the cells for other 5’ while shaking. GSCs and
media were collected on ice and centrifuged at 2000 rpm for 5’ at 4C. The
pellets were washed in cold PBS containing protease inhibitor and spin it again
using the same settings. The cells pellets were then washed once more before
to be flash frozen at -80. The samples were delivered to Prof. Kunal Rai’s
laboratory for Chip sequencing.
3
R E S U LT S
3.1. stratifying patients by taz expression
It is a now well-established fact that TAZ expression is significantly different
between the IDH WT and mutant samples, wherein owing to the G-CIMP phe-
notype, TAZ is significantly suppressed through promoter hyper-methylation
[42]. This is visualized in Figure 1. It is clear from this figure that about 75%
of the IDH mutant samples have TAZ expression lower than 75% of the WT
samples.
In order to further study the impact of differential TAZ expression on the
brain tumor biology, we decided to stratify samples into TAZ-low and TAZ-
high groups based on TAZ expression. Since expression of TAZ is significantly
lower in the IDH mutant samples (Figure 1), only the WT cases were used
to identify empirical expression-level cut-offs for stratification. The lower and
upper terciles of log-TAZ expression in the IDH-WT cases were used as cut-
offs. We decided to go with terciles in order to retain a large proportion of
samples in the analysis, while at the same time being able to draw contrast
between the two groups. Whether these cut-offs are biologically relevant is
30
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Figure 1.: Expression of TAZ varies significantly with IDH mutation status,
owing to promoter hypermethylation resulting from the CpG Island
hypermethylation phenotype.
verified post-hoc by comparing the expression profiles of gliomas that have
been grouped herein. Figure 2 shows the log-TAZ expression in the IDH-WT
samples, with their lower and upper terciles marked by the dotted lines.
The empirically derived cutoffs (< 10.08 for TAZ-low and > 11.11 for
TAZ-high) were used to stratify all clinical samples into these clusters (TAZ-
low, TAZ-high and other). The resulting distribution of TAZ-clusters with IDH-
mutation status is shown in Table 1. As expected, the IDH mutant samples are
all predominantly TAZ-low, and by construction, the IDH WT samples show
an even distribution between TAZ-low and TAZ-high groups.
IDH status TAZ high TAZ low
Mutant 19 341
WT 79 77
Table 1.: Distribution of TAZ expression status with sample IDH status. Nearly
all the IDH mutant samples are grouped into the TAZ low class, as
expected.
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Figure 2.: Histogram of TAZ expression in IDH WT samples. The dotted lines
show the lower and upper terciles, which identify the TAZ low and
TAZ high samples
3.2. taz associated signatures in idh-wt gliomas
It is well-known that the underlying genetic and epigenetic landscapes are
very different between the IDH-MUT and IDH-WT gliomas [29, 20]. In order
to keep the data interpretation simple and avoid questions about effects of
confounding variables, we first present results from analysis restricted to the
IDH-WT samples.
Differential expression analysis of the IDH-WT TAZ-high versus TAZ-
low gliomas identified 832 upregulated and 1353 downregulated genes at a
Fold change cutoff of 1.5× and an FDR cutoff of p < 0.05. Figure 3 shows a
heatmap of expression of these genes, centered and scaled to have zero mean
and unit variance across the IDH-WT gliomas under comparison. With unsu-
pervised hierarchical clustering of the columns, samples with high and low-
TAZ expression show a tendency to cluster together. Gene Ontology enrich-
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ment analysis of these differentially up and downregulated genes is shown in
Figure 4. Genes that are downregulated with high TAZ expression are signif-
icantly enriched for neuronal activity related processes while the upregulated
genes show significant enrichment for immune signaling, extracellular matrix
binding binding and other prototypical MES processes.
TAZ
Grade
−1
0
1
2 TAZ.low
TAZ.high
G2
G3
GBM
Figure 3.: Heatmap of the 2185 genes that are differentially expressed across
156 IDH WT samples with high/low TAZ expression. Visualized is
the scaled expression (z-scores) of each gene across samples.
The shift in Transcriptional activity from a neuronal to a more mesenchy-
mal state is also reflected in the Transcription subtype assigned to these glioma
cases using the gene signatures defined in Verhaak et al 2010 [36], as visualized
in Figure 5. Samples with a higher level of TAZ expression show a shift from
the PN to MES state.
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Figure 4.: Enrichment analyses show that significant trends in covariation of
groups of genes with TAZ expression. Size of the balls indicate
number of genes from the pathway that are up or downregulated,
and their color reflects the FDR for enrichment. We can see a shift
in gene expression from neurogenic to mesenchymal signature with
increased TAZ expression.
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Figure 5.: TAZ expression versus Transcriptome subtype in IDH wt gliomas.
The horizontal lines represent cut-offs used to define TAZ-low and
TAZ-high groups. CL: classical, ME: MESenchymal, NE: Neuronal,
PN:Proneural
3.3. influence of differential tumor purity
Since these are bulk tumor samples, there is potential infiltration of immune
and stromal cell types within the tumor microenvironment, the extent of which
could vary across samples. It has been argued before in Aran et al 2015 [80]
that not accounting for the variability in tumor purity across samples while
analyzing the expression data can produce spurious results. I downloaded the
Tumor purity scores for the TCGA-glioma cases provided in this paper to use
with my analysis.
Figure 6 shows the distribution of tumor purity scores with TAZ expres-
sion for the IDH-WT gliomas. A significant negative correlation (Spearmann
rho = -0.41) is observed between tumor purity and TAZ expression. It there-
fore becomes imperative that in comparing expression profiles of TAZ-high
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and TAZ-low samples, we must account for the confounding effects of tumor
infiltration.
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Figure 6.: Distribution of sample tumor purity with TAZ expression. Spear-
mann correlation ρ = −0.41, pvalue = 8.61e − 11. Tumor purity
decreases with increasing TAZ expression.
Differential expression analysis between these two groups of samples
was repeated by including the sample purity scores as an additive effect in the
design matrix [80]. A lot fewer genes now passed the same significance thresh-
olds of 1.5× fold change and FDR < 0.05. Specifically, only 295 genes were
upregulated and 706 downregulated with high TAZ expression. Since higher
TAZ expression correlates with lower tumor purity, one could argue that this
observation is as expected, since the genes that dropped out are potentially
expressed by the infiltrating stromal and immune cells in the tumor microen-
vironment (TME). Enrichment analysis for genes that dropped out upon con-
trolling for tumor purity is shown in Figure 7 and validates this claim. Specifi-
cally, the genes upregulated with TAZ that are strongly correlated with tumor
purity are a variety of immune signaling genes, and the downregulated genes
are those involved in neuronal processes.
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Figure 7.: Enrichment analysis of differentially expressed genes that drop out
upon controlling for tumor purity. A total of 609 and 776 genes up
and down-regulated respectively with high TAZ expression show
strong association with tumor purity and are enriched for MES (im-
mune signaling) versus neuronal functions.
Figure 8 shows enrichment analysis results for genes passing the signifi-
cance threshold after controlling for tumor purity. The plot looks very similar
to Figure 4, with just fewer genes in the corresponding pathways. Thus our
observation of a suppressed Neuronal state and activated MES state appear to
be independent of the effects of infiltrating cells.
Multiple recent reports have shown that high TAZ expression causally
drives higher immune infiltration in gliomas [32, 102]. As a result, several
genes that show strong correlation with tumor purity are going to be tumor-
intrinsic signals [40]. Having shown that correcting for tumor purity does
not change our fundamental observations of TAZ driving a PN to MES shift,
I refrain from controlling for this co-variate in subsequent gene expression
analyses.
Thus far we have established the fact that differential TAZ expression is
consequential even at the range to which it varies within the IDH-WT gliomas.
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Figure 8.: Pathway enrichment of differentially expressed genes after account-
ing for tumor purity estimates.
Observed clinical and molecular effects of TAZ variation are not just because
of this variable confounding with sample IDH status.
3.4. taz associated signatures across all gliomas
We saw in Figure 1 that TAZ expression is significantly lower in the IDH-
MUT samples compared to the IDH-WT samples. Therefore, in order to fully
understand the consequences of differential TAZ expression in gliomas, we
chose to study the samples that show maximum variation.
3.4.1. identifying the cases of interest
In choosing to compare the transcriptional signatures of samples with extreme
levels of TAZ expression, we are inevitably comparing gliomas with very differ-
ent genetic backgrounds [20]. As a consequence, some of the obtained results
will be false positives that are caused by other confounding variables than di-
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rectly by differential TAZ expression. However, given the established roles
of TAZ in driving a range of the hallmark cancer phenotypes [64], we herein
assume that most results obtained will be causal effects of variation in TAZ
expression. These results are verified with in vitro experiments later.
Figure 9a shows the empirical cumulative distribution function (eCDF)
of TAZ expression across all the TCGA glioma samples. For each value on
the X-axis, the y-axis shows the fraction of samples with TAZ expression less
than that value. The red line shows the cut-off used to define TAZ high cases
in IDH wt samples, which corresponds to a CDF of ≈ 0.85, as indicated by
the blue dotted line. An equal proportion (15%) of samples with the lowest
expression levels of TAZ were then labeled TAZ-low. The dotted lines in Figure
9b indicate the cut-offs used for identifying these cases.
The interaction of TAZ status defined thus with sample IDH status is
shown in Table 2. As expected, the TAZ-high samples are primarily all IDH-
WT and the TAZ-low samples IDH mutants.
IDH status TAZ.high TAZ.low
Mutant 19 89
WT 79 9
Table 2.: Distribution of TAZ expression groups of samples with IDH mutation
status.
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(a) Empirical CDF of TAZ expression across all samples. The red
line shows the cut-off used to identify TAZ-high cases in IDH
wt samples.
TAZ expression across all cases
log2 TAZ Expression
Fr
eq
ue
nc
y
6 8 10 12 14
0
50
10
0
15
0
TAZ lower limit
IDHwt lower limit
IDHwt upper limit
(b) Histogram of TAZ expression across all cases, with dotted
lines indicating the various cutoffs used.
Figure 9.: Stratifying cases by TAZ expression levels, and the cutoffs used for
the same.
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3.4.2. differential expression analysis
The RNA-seq data from outlier samples identified above were analyzed with
DESeq2 for differential gene expression.
Since both the IDH mutation status as well as tumor purity estimates
co-vary with TAZ status, these factors were not controlled for in performing
differential expression analysis. At a significance threshold of FDR < 0.05
and a two-fold change in expression, a total of 1790 genes were found to be
upregulated and 1416 genes downregulated with high TAZ expression.
Compared to our analysis in previous sections of the TAZ-high versus
TAZ-low groups of IDH-WT gliomas, the number of genes upregulated with
TAZ expression is nearly twice as many (1790 versus 832). Moreover this is
observed at a higher significance threshold of two-fold change in expression,
compared to 1.5× used earlier. Figure 10 shows the heatmap of expression of
these genes across the 196 samples. We can observe a clear distinction between
the expression profiles of TAZ-low and TAZ-high gliomas. We can also see a
number of IDH mutant TAZ-high samples clustering together with the other
mutants. Interestingly, they appear to have a hybrid expression signature be-
tween the two extreme clusters. We can also see a trend in the distribution
of tumor grades, with all GBM samples having high TAZ expression and the
corresponding signatures.
Given the several thousand genes that are differentially expressed be-
tween these two clusters of patients, it is evident that these gliomas are pretty
much different diseases, driven by tumor cells in potentially different cell
states. It is however interesting to speculate that the reason underlying this,
and at least a few other observations made regarding different courses of dis-
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Figure 10.: Heatmap of scaled expression of the identified differentially ex-
pressed genes between TAZ low and TAZ high samples.
ease and clinical outcomes between the IDH-WT and IDH-MUT gliomas, is
the difference in levels of TAZ expression. While at this point this reasoning
is very much speculative, we show using in vitro studies that TAZ overexpres-
sion by itself drives large scale epigenetic changes within the cells, and flips
the switch between its transcriptional states through activation and repression
of specific master regulatory factors.
Figure 11 shows Enrichment analysis results for these genes. High TAZ
expression is associated with a PN to MES switch in clinical glioma samples.
In conclusion, we have seen that the expression of several thousand
genes co-vary with TAZ expression in clinical glioma samples. The genes that
are downregulated are predominantly neuronal, and genes upregulated are
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Figure 11.: GO enrichment analysis for genes differentially expressed between
TAZ-high and TAZ-low glioma samples.
predominantly mesenchymal in nature. A range of immune response genes
are upregulated with high TAZ expression, which could be both cause (expres-
sion of cytokines and chemokines that attract myeloid immune cells into the
tumor microenvironment), and effect (expression patterns in these infiltrating
immune cells).
3.4.3. master regulatory analysis
Given the very large number of genes that are differentially expressed, and the
fact that they are significantly enriched for specific pathways that we can iden-
tify as Neuronal and MESenchymal, it is likely that aberrant TAZ expression
is associated with systemic effects in the regulatory landscapes of these cells.
I therefore performed Master regulator analysis with the list of up and down-
regulated genes from the previous analysis (Figure 10) using the online tool
ChEA3 [89]. This tool helps us identify potential upstream regulators of our
list of query genes by performing an over-representation analysis with known
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regulomes of individual transcription factors. The regulomes themselves are
documented from multiple different sources of data, and enrichment results
from these different databases are integrated to provide a final ranked list of
Master regulators [89].
I used ChEA3 to prioritize the top 100 master regulators for the list of up
and down-regulated genes respectively. Significant portions of these transcrip-
tion factors (41% and 36% respectively) are themselves differentially up and
down regulated with high TAZ expression. The list of upregulated factors in-
clude CEBPB, CEBPD, TWIST1, SNAI2, FOSL1, JUN, JUNB and several other
prototypical regulators of MESenchymal transformation in cancer. The list
of downregulated genes includes OLIG1, OLIG2, MYT1L, NEUROD2, NEU-
ROD6, NEUROD4, ASCL1 and other powerful regulators of neurogenesis.
Figure 12 shows a correlation plot of the differentially expressed Master
regulators in the two TAZ-expression groups. We can see these Transcription
factors forming two cliques, showing strong positive correlations in expression
within the groups, and negative correlation without. TAZ expression shows
strong positive correlation with the MES signature and negative correlation
with the PN signatures. Given this vast difference in the core regulatory cir-
cuits of these tumor cells, it is no longer surprising that their transcriptomes
are as drastically different as we see in Figure 10.
3.4.4. conclusions from analysis of tcga data
By stratifying the TCGA samples by TAZ expression levels and analyzing their
transcriptomes, we have so far seen that high TAZ expression is associated
with a shift of the tumor cells from a PN to MES states. We see this effect con-
sistently independent of sample IDH status, although its consequences appear
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Figure 12.: Gene expression correlation plot for the differentially expressed
Master regulator genes shows the presence of distinct transcrip-
tional regulatory circuits in the two TAZ expression clusters.
most when comparing the IDH mutant and the WT samples owing to their
very large difference in levels of expression of TAZ. Master regulatory anal-
ysis showed that TAZ is strongly correlated with expression of transcription
factors associated with the distinct states. These transcription factors appear
to have strong feed forward and feed-back effects, reinforcing expression of
their own clusters and inhibiting the other cluster of master regulators. As
we discussed in the introduction, these different states are very likely to be
caused and reinforced through epigenetic alterations [48]. Furthermore, at this
point we speculate that these changes are indeed effected by differential TAZ
expression [68].
In order to establish causality, we generated and analyzed sequencing
data for gene expression and chromatin modification marks from glioma stem
cells cultured in vitro with differential TAZ activity.
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3.5. demonstrating causality of observed gene expression patterns
Two mutant forms of the TAZ protein have been previously characterized,
namely TAZ-4SA and TAZ-S51A [42]. These are both mis-sense mutations
that affect TAZ activity. The 4SA protein has a mutation at the site of phospho-
rylation by the Hippo kinases, as a result of which it is never expelled from
the nucleus and is thus constitutively active. The S51A mutation affects TAZ
binding to the TEAD family of Transcription factors. Since the TAZ-TEAD in-
teraction is essential for nearly all its downstream effects [64], this protein is a
functionally inactive variant of TAZ. The above information is summarized in
Figure 13 for easy reference.
Figure 13.: Summary of nature and activity of TAZ variants used for in-vitro
studies
We generated RNA seq profiles of the GSC-11 cell lines with overexpres-
sion of Vector, 4SA and S51A constructs in triplicates. GSC-11 is an IDH-WT
patient derived glioma cell line with a PN transcriptional signature, allow-
ing us to see if TAZ overexpression by itself drives the PN to MES transition.
Figure 14 shows the PCA plot for the nine samples. The samples with and
without TAZ activity form distinct clusters at the far ends of the PCA plot.
Vector and S51A samples cluster together, indicating that functional effects of
TAZ overexpression are contingent upon TEAD binding.
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Figure 14.: PCA plot of GSC-11 cells overexpressing Vector, 4SA or S51A. Vec-
tor and S51A have no TAZ activity and cluster together, while 4SA
having high TAZ activity clusters separately.
Differential gene expression analysis identified 1367 genes upregulated
and 1071 genes downregulated with high TAZ activity at significance thresh-
olds of FDR < 0.05 and 2× fold change. Nearly 12% of all expressed genes
thus pass the significance thresholds, indicating that TAZ overexpression alone
drives significant changes in the transcriptional states of the cell. Scaled expres-
sion of these genes is visualized in Figure 15.
Enrichment analysis results are shown in Figure 16. This figure is ex-
tremely illustrative. The trends reported are nearly identical to our observa-
tions from the analyses of bulk tumor samples in Figures 4 and 11. Genes
downregulated by TAZ are predominantly neuronal, and the ones upregulated
are MESenchymal. Moreover, it shows a glioma cell intrinsic upregulation of a
number of Immune signaling and response genes, providing a-posteriori sup-
port for our decision to not control for tumor purity estimates in the analyses
of bulk samples. These results provide strong evidence that overexpression of
the single protein TAZ in glioma cells shift effects a PN-to-MES cell state tran-
sition, with resulting differential expression of thousands of genes. To see if
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Figure 15.: Heatmap showing scaled expression of 3805 differentially ex-
pressed genes with TAZ overexpression.
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these changes are accomplished through systematic epigenetic reprogramming
of the glioma cells by TAZ, ChIP-seq data for a range of histone modification
marks indicative of differential genome regulatory activity were generated and
analyzed.
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Figure 16.: Gene Ontology Enrichment analysis results for in-vitro TAZ over-
expression studies show that TAZ activity drives the PN-to-MES
transition in cancer cell state.
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3.6. chip-seq analysis
We generated ChIP-seq data for active chromatin marks Histone H3 lysine-27
acetylation (H3K27ac), lysine-4 mono- and tri-methylation (H3K4me1, H3K4me3)
in the GSC-11 parental cell lines transfected with vector, TAZ, 4SA and S51A.
H3K27Ac marks active regulatory regions both proximal and distal to the tran-
scription start sites (TSSs), H3K4me1 is a mark of active promoter regions prox-
imal to TSSs, while H3K4me1 is a mark of poised and active distal enhancer
sites.
ChIP-peaks were called using MACS2 [93]. Differential peaks for each hi-
stone mark were called between the Vector and 4SA-transfected samples using
MACS. We contrasted Vector with S51A since it had the better enrichment pro-
file as compared to S51A samples. The super-enhancer calling program ROSE
[94] was used to prioritize differential regions having the strongest enrichment
signals for downstream visualization and analysis. For H3K27Ac marks, this
identified 993 strongly differentially enriched regions in Vector and 1173 re-
gions in 4SA-transfected samples. Signal intensity at the 10kb regions about
the center of these differential peaks is visualized in Figure 17. There are ex-
tensive changes in the deposition of histone acetylation marks in the cancer
cell’s genome with TAZ overexpression. Regulatory regions that are normally
active in the cell’s ground state have complete loss of active enhancer marks,
which are now gained in very different regions of its genome.
Super-enhancers were called by stitching together the H3K27Ac peaks
within 12.5kb of each other and identifying genomic regions with the strongest
cumulative signal intensities using the ROSE algorithm [94]. This identified
610 super enhancer regions in the vector, and 976 super enhancer regions in
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Figure 17.: Heatmap showing histone H3K27Ac signal intensity at differen-
tial enhancers between vector and 4SA-overexpressing GSC11 cells.
The upper row (blue color profile) shows genomic regions with 4SA
specific peaks, and lower row shows regions with Vector-specific
peaks (green color profile). Signal intensity in the 10kb region about
individual peaks are visualized. The visualized signal is the input-
subtracted, RPKM-normalized sequenced read counts at these sites.
the 4SA samples. H3K27Ac profiles in the flanking 500kb regions of these
peak centers are visualized in Figure 18. While there is some overlap in the
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Figure 18.: H3K27Ac profiles surrounding 500kb regions about the center of
Super enhancer peaks in Vector and 4SA samples shows the change
in SE landscape of the cell with TAZ overexpression. Blue line
shows the Vector-specific profile and green line shows 4SA-specific
profile.
super enhancer regions between the two cell states (accounting for the baseline
levels of the alternate profile), they predominantly occupy distinct regions of
the genome.
By mapping the super enhancer regions to the differentially active target
genes, we verified that the super enhancer domains are significantly enriched
to regulate the corresponding PN and MES target genes.
We mapped the super enhancer regions to the target genes identified in
Figure 15 and used the Fisher’s exact test to see if the super enhancer domains
specifically regulate these genes. Results of this analysis is shown in Figure 19.
The super enhancer regions in vector and 4SA samples are significantly more
likely to regulate the corresponding highly expressed genes. This result shows
that TAZ-mediated epigenetic reprogramming and changes in super enhancer
landscape causally drives the transition in transcriptional signatures of glioma
cells.
The Histone H3K27Ac marks about the transcription start sites of a few
representative PN and MES master regulators and signature genes are visual-
ized in Figure 20. Strong H3K27Ac signal about PN genes seen in Vector sam-
ples are predominantly completely lost with TAZ overexpression, and MES
genes are activated. Interestingly, STAT3 and CEBP-B/CEBP-D show strong
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Figure 19.: Fisher’s exact test shows significant enrichment of Vector and 4SA
super enhancer domains in the regulatory regions of the corre-
sponding highly expressed genes compared to background. The
enrichment is lost when we interchange tha targets i.e. the vector-
specific SEs are no less or more likely to regulate the TAZ-specific
genes than background genes, and vice versa.
gain in signal intensity with TAZ treatment. Given that these factors have been
established as Master regulators of MES transformation in gliomas [41], TAZ
could possibly be acting upstream of these factors, driving their expression
through epigenetic reprogramming.
Similar differential peak calling analysis with the histone H3K4me3 marks
for active transcription start sites identified 591 vector-specific and 710 4SA-
specific regions with very strong signals. The enrichment marks about these
ChIP-peaks are visualized in Figure 21. Mapping the differential peaks to clos-
est TSSs within 5kb regions showed that the vector-specific promoter regions
are strongly associated with regulating neuronal processes. This included Mas-
ter transcription factors such as OLIG1, OLIG2, HES1, POU3F2, ZEB1 and mul-
tiple SOX family proteins that are all involved in regulating different steps of
neurogenesis. Loss of active promoter marks about the TSSs of some represen-
tative master regulators of neurogenesis with high TAZ expression is visual-
ized in Figure 22.
3.6 chip-seq analysis 54
(a
)
H
3K
27
A
c
m
ar
ks
ab
ou
t
PN
m
as
te
r
tr
an
sc
ri
pt
io
n
fa
ct
or
s.
sc
al
e
:0
-1
00
un
it
s
(b
)
H
3K
27
A
c
m
ar
ks
ab
ou
t
M
ES
re
gu
la
to
rs
an
d
si
gn
at
ur
e
ge
ne
s.
sc
al
e
:0
-1
75
un
it
s
Fi
gu
re
20
.:
H
3K
27
ac
R
PK
M
-n
or
m
al
iz
ed
pe
ak
s
vi
su
al
iz
ed
ab
ou
t
th
e
ne
ig
hb
or
ho
od
of
re
pr
es
en
ta
ti
ve
PN
an
d
M
ES
ta
rg
et
ge
ne
s.
Th
e
re
d
la
ne
s
in
di
ca
te
pe
ak
s
in
TA
Z
-o
ve
re
xp
re
ss
in
g
ce
lls
,a
nd
th
e
bl
ue
la
ne
in
di
ca
te
s
ve
ct
or
co
nt
ro
l.
3.6 chip-seq analysis 55
Figure 21.: Heatmap showing H3K4me3 signal intensity abot 10kb region sur-
rouding the differential peaks in vector and 4SA samples. The blue
line indicates signal profile in vector-specific regions, and the green
profile shows the 4SA-specific regions. There is significant loss of
signal intensity about the vector-specific proximal regulatory sites
with high TAZ expression.
To summarize, we have shown here that TAZ overexpression in glioma
cells drives epigenetic alterations with extensive repositioning of active chro-
matin regions in the genome. A variety of histone modification marks in
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Figure 22.: H3K4me3 marks for active promoter sites about the transcription
start sites of representative Proneural master regulators shows near-
complete loss of signal intensity with TAZ overexpression, under-
lying epigenetic silencing of neuronal signatures.
the cell are altered, and an alternate super enhancer landscape is established.
Through these effects, TAZ is able to activate and suppress distinct sets of
master regulator genes of the MES and PN states respectively, and drive the
shift in cell state. Importantly, all of the observed effects of epigenetic and
transcriptional effects of TAZ overexpression are contingent upon binding to
the TEAD factors. The S51A samples in all cases had profiles that mirrored the
vector control. The exact nature of regulatory interactions that TAZ has with
chromatin remodeling complexes, and the transcriptional regulatory circuits
that lie downstream of TAZ and helps effect this transformation is something
we would like to study further and report in our upcoming manuscript.
4
D I S C U S S I O N S
In Bhat et al 2011 [42], it was shown that overexpression of the single tran-
scriptional coactivator TAZ is sufficient to drive a PN to MES transformation
of glioma stem cells and drive malignant transformation of gliomas in vivo.
Since distinct cell states are established by the activities of master regulatory
factors and reinforced by epigenetic forces that maintain chromatin states, I
hypothesized that TAZ effects this observed PN-to-MES transformation by al-
tering the epigenetic landscapes of the tumor cells. This disturbance in the
potential energy landscape now leads to the attainment of a new steady state
determined by the once-dormant MES core regulatory circuitry of these cells.
We have seen in this thesis repeatedly that high TAZ expression drives cells
from a PN to MES expression state, independent of sample IDH mutation sta-
tus, and independent of the influences of tumor micro-environment on the
gene expression signatures. We saw that the master regulators controlling
these cell states are coordinately up and down-regulated with varying TAZ ex-
pression. TFs controlling cell cycle exit and terminal differentiation of neural
precursor cells (NPCs) such as ASCL1, NEUROD4, POU3F1, MYT1, MYT1L
etc [103] are strongly suppressed by TAZ, while drivers of the MES state such
57
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as CEBPB, SNAIL, TWIST, the AP1 proteins, TEAD family of TFs and other
regulators [104] are strongly upregulated.
By analyzing ChIP-seq data for histone modification marks such as H3K27
acetylation, H3K4me1 and H3K4me3 which are indicators of active promoter
and enhancer elements [59], we saw that TAZ overexpression drives large
shifts in the epigenetic landscapes of the glioma stem cells. Regulatory re-
gions associated with the PN factors lose their active histone marks while the
genomic regions associated with MES target genes show strong enrichment
for these signals. These shifts in chromatin states are potentially mediated by
YAP/TAZ-TEAD interaction with chromatin remodeling complexes [68]. We
have unpublished data showing that treating TAZ-overexpressing GSCs with
the HDAC inhibitor Vorinostat releases expression of the PN regulators, indi-
cating potential roles of the NuRD complex in TAZ mediated gene silencing
[73].
Interestingly, YAP activity has previously been reported to be critical for
maintaining the pluripotent stem cell populations of the nervous system, with
loss of YAP activity, either through gene silencing or through activation of the
Hippo signaling pathway, leading to neuronal differentiation [105, 106, 107,
108]. Negative feedback loops have been described between YAP activity and
the expression of PN factors like ASCL1 and NEUROG2, each inhibiting the
expression of the other, and their balance being important for maintaining the
progenitor cell populations during neurogenesis [106]. Importantly, it has been
reported in these studies that loss of YAP activity is a necessary precondition
to have terminal neuronal differentiation, with YAP over-expression silencing
expression of the PN factors and preventing cell cycle exit and differentiation.
This is consistent with our observations that YAP/TAZ overexpression leads
to suppression of the neuronal phenotype in glioma cells.
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Malignant gliomas and glioblastomas are driven by a subset of cells
within the tumor microenvironment with stem cell properties that underlie the
hyper-proliferation, tumor initiation and metastasis capacity and treatment re-
sistance [109]. The highly heterogeneous nature of cells in the tumor indicates
a failure in stem and progenitor cell differentiation as a hallmark of this dis-
ease. There is therefore growing interest in developing strategies for directed
neuronal differentiation of these glioma stem cells as a therapeutic strategy
for treating patients [110, 111, 112, 113]. Neurons are terminally differentiated
cell types that are post-mitotic and resistant to cell cycle re-entry. Recent work
has shown that late stage neural progenitors are resistant to neoplastic trans-
formation even with loss of powerful GBM-relevant tumor suppressor genes
like NF1, PTEN and TP53 [114]. Moreover, overexpression of PN transcription
factors ASCL1 and MYT1/MYT1L have been shown to induce neuronal differ-
entiation of the glioma stem cells and significantly impair GBM growth in vivo
[113, 115].
We therefore conclude our work by stating that suppression of TAZ
activity in malignant gliomas is a necessary prerequisite for expression of
PN master regulators in the tumor cells, induce terminal differentiation, and
thereby halt tumor growth. Developing therapeutic drugs that could target
TAZ and/or its interactions with other molecular players like TEADs and
HDACs are therefore potential avenues to explore in finding a cure for this
cruel disease.
A
S U RV I VA L A N A LY S E S
Survival data for 661 TCGA samples was downloaded from Liu et al 2018 [76],
and used in conjunction with other clinically relevant variables to determine
if TAZ expression is a significant prognostic factor even after accounting for
other well-known predictors of patient survival. Univariate Cox regression
analysis of sample TAZ expression against the Progression Free Interval (PFI)
time gave significant results (Hazard Rate (HR) = 1.5, pvalue < 2e-16). Univari-
ate Cox models were also fit for other well-known molecular markers of patient
outcome such as IDH status, Chr 7 amplification and Chr 10 deletion, 1p-19q
codeletion, ATRX mutation, MGMT and TERT promoter status, as well as de-
mographic factors such as patient gender and age at disease diagnosis. Results
of these regression models are shown in Table 3. The Risk Factor indicates the
feature that was tested for significance, coef indicates the proportional hazards
(PH) model coefficient with respect to a baseline level (in alphabetic order for
the corresponding factors. For example, for IDH status IDH-Mutant is baseline
and the increased hazard rates for IDH-WT samples are displayed), exp(coef)
indicates the corresponding Hazard Rate for the feature, z-value indicates the
value of test statistic and Pr(> |z|) shows the p-value.
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Summary of univariate Cox analysis
Risk factor coef exp(coef) z Pr(>|z|)
Age 0.042 1.043 10.1 5.53E-24
Gender 0.037 1.038 0.32 0.749212
Chr.7.gain.Chr.10.loss -1.73 0.177 -13.401 5.95e-41
Chr.19.20.co.gain -1.178 0.308 -5.446 5.15e-08
IDH.status 1.976 7.216 15.52 2.66e-54
Mutation.Count 0.033 1.034 12.106 9.75e-34
Percent.aneuploidy 1.865 6.453 7.063 1.63e-12
Chr.1p.19q.codeletion 1.208 3.347 7.014 2.32e-12
MGMT.promoter.status 1.087 2.965 8.607 7.47e-18
TERT.promoter.status -0.575 0.563 -3.237 1.206e-3
ATRX.status 0.476 1.61 3.623 2.92e-4
TAZ.expression 0.407 1.502 9.490 2.30e-21
Table 3.: Summary of results from Univariate Cox regression analysis of known
risk factors with patient PFI data. TAZ expression is associated with
significantly high risk.
The Hazard rate (column 3 in Table 3) is a multiplicative factor that in-
dicates the change in rate of occurrence of event with phenotype, with respect
to some baseline. Thus for binary variables like IDH status, this data indicates
that at any point in time, an IDH-WT sample is seven times as likely to have
an event compared to an IDH-MUT sample that that has also survived up to
that point. The proportional hazards model assumes that this ratio does not
change with time, hence the name. For continuous variables, this column indi-
cates the change with every unit increase in value of the variable. Thus there is
a 1.5× increase in rate of event associated with every two-fold increase in TAZ
expression level (unit change in log TAZ expression). Given that the range of
TAZ expression in these samples was 5-13 units (log normalized counts), this
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translates to a 25x higher Hazard rate in samples with the highest expression
of TAZ compared to the lowest.
It is seen that all the tested factors except patient gender are highly signif-
icant prognostic factors (p-value < 1e-3). Given this result, and the fact that a
lot of the molecular features considered co-vary with IDH status, the samples
were stratified by IDH mutation status and then tested using a multivariate
Cox model to see if TAZ expression remains a significant predictor of survival.
Results from this analysis are shown in Table 4.
Summary of Multivariate Cox analysis after stratifying by IDH status
Risk factor value coef exp(coef) z Pr(>|z|)
TAZ.expression 0.14 1.15 0.06 0.013
Age 0.02 1.02 3.88 1.04e-4
Chr.7.gain.Chr.10.loss No combined CNA -0.13 0.88 -0.66 0.51
Chr.19.20.co.gain No chr 19/20 gain 0.35 1.42 1.32 0.19
1p.19q.codeletion non-codel -0.025 0.98 -0.087 0.93
MGMT.promoter.status Unmethylated 0.07 1.07 0.45 0.65
ATRX.status WT -0.53 0.59 -2.098 0.04
Table 4.: Results of Multivariate cox regression after stratifying cases by IDH
status. TAZ expression remains a significant risk factor.
TAZ expression remains a significant prognostic factor after controlling
for sample IDH status, although the magnitude of the effect (Hazard rate =
1.15 per 2-fold increase in expression) is now significantly reduced. Effect of
TAZ expression on patient survival is therefore significant but not very drastic.
Figure 23 shows a Kaplan-Meir plot for the survival times of the TAZ-
low and TAZ-high glioma cases defined in Table 1. The log-rank test p-value
is computed after stratifying the cases by their IDH status. Although TAZ
expression remains a significant prognostic factor, the difference in survival
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curves between the TAZ-low and TAZ-high groups is not very drastic, espe-
cially when juxtaposed with the effects of IDH mutation status.
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Figure 23.: Kaplan-Meir plot of samples classified by their TAZ expression lev-
els. The samples were stratified by their IDH mutation status for
computing the log-rank test p-value.
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